Navigation Links
A revolutionary new model for Alzheimer's disease
Date:2/19/2009

A study from the Buck Institute for Age Research offers a revolutionary new model for Alzheimer's disease (AD), a devastating neurodegenerative disorder which afflicts 24 million people worldwide. In an effort to unravel the normal function of a protein implicated in AD, scientists in California and France have discovered a naturally occurring protein that provides a new therapeutic target for the disease. The finding upsets the current theory that AD is a disease of toxicity stemming from damage caused by sticky plaques that collect in the brain this research points to the condition as a disorder involving an imbalance in signaling between neurons. The study appears online in the Nature publication Cell Death and Differentiation.

One of the mysteries of AD has been the normal function of the amyloid precursor protein (APP) which are concentrated at the points where neurons connect. Even though the sticky amyloid plaques which have been viewed as a hallmark sign of AD result from APP, it seems unlikely that APP exists simply to cause Alzheimer's disease. In their study, scientists from the Buck Institute and the CNRS (Centre Nationale de la Recherche Scientifique) show that APP binds to netrin-1, a protein that helps to guide nerves and their connections in the brain, as well as helping nerve cells to survive. When netrin-1 was given to mice that have a gene for Alzheimer's disease their symptoms were reversed, and the sticky amyloid was reduced. These results suggest that the long-held belief that AD is caused by brain cell damage inflicted by the amyloid plaques may be wrong; instead, it is beginning to appear that the disease stems from an imbalance between the normal making and breaking of connections in the brain, with netrin-1 supporting the connections and the amyloid breaking the connections -- both by binding to APP and activating normal cell programs. Not only did the netrin-1 binding to APP keep the nerve cells alive and connect
'/>"/>

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-717-3268
Buck Institute for Age Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Old developmental pathways spawn revolutionary evolutionary changes
2. M2SYS Introduces Revolutionary Biometric Artificial Intelligence Technology to Significantly Reduce Fingerprint Software False Reject Rates
3. Revolutionary CO2 maps zoom in on greenhouse gas sources
4. Revolutionary chefs? Not likely, shows physics research
5. Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy
6. Clemson chemists present revolutionary teaching concepts
7. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
8. A new kind of rat model
9. JILA finds flaw in model describing DNA elasticity
10. Smithsonian researchers develop models to assess wetland health
11. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Oslo, April 7, 2010: OptiNose, a leader in ... publication in Cephalalgia of results from its ... of its novel, intranasal drug/device product for the treatment ... and 20mg doses administered intranasally using OptiNose,s bi-directional delivery ...
... to exercise, help may be on the way. That,s ... as exercise, promotes new bone growth. This opens the ... into thinking they are getting a workout. The research ... FASEB Journal ( http://www.fasebj.org ). This ...
... Calif.) African-American women have poorer survival rates ... whether they receive radiation therapy following lumpectomy or ... Martinez, assistant professor of surgery at UC Davis ... women with advanced breast cancer are less likely ...
Cached Biology News:OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2For osteoporosis patients, exercise pill one step closer to reality 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
(Date:7/2/2015)... GLASGOW, Scotland , July 2, 2015 ...   Bio-tech procurement company Amici Procurement has ... IOM) to help it move to Office 365. ... Procurement provides small to medium-sized companies in the ... with all aspects of the purchasing cycle to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, ... over 20,000 brain scans and is believed to be the largest brain imaging study ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is ... the molecular diagnostics industry. BCC Research reveals in its new report that the market ... costs, and a growing need for better diagnostics as part of a molecular diagnostics ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... DIEGO , March 16  Neurocrine Biosciences, Inc. (Nasdaq: ... recently completed public offering of common stock has exercised in ... common stock to cover over-allotments.  The sale of the additional ... into account the sale of the additional shares at a ...
... Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of ... release tablets,INTUNIV(TM). , ... , ... ...
... LONDON, ON , March 16 /PRNewswire/ ... protein therapeutic, demonstrated positive results in a pivotal proof ... model for arthritis. VT-346 achieved a statistically significant, dose ... prevented deterioration due to disease in terms of weight ...
Cached Biology Technology:Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 2Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 2Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 3Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 4
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: